Deuruxolitinib
50 interactions 21 cited referencesRead the full Deuruxolitinib drug information page
Medically reviewed by
Dr. Brian Staiger, PharmD, BCPS
· Updated Aug 10, 2026
· Editorial policy
· Data sources
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Contraindicated
Deuruxolitinib Adagrasib Krazati Increased deuruxolitinib exposure and an increased risk of deuruxolitinib-related adverse effects such as thrombosis Details Deuruxolitinib Amiodarone Nexterone Increased deuruxolitinib exposure and an increased risk of deuruxolitinib-related adverse effects such as thrombosis Details Deuruxolitinib Cannabidiol Epidiolex Increased deuruxolitinib exposure and an increased risk of deuruxolitinib-related adverse effects such as thrombosis Details Deuruxolitinib Ensitrelvir Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Deuruxolitinib Fluconazole Diflucan Increased deuruxolitinib exposure and an increased risk of deuruxolitinib-related adverse effects such as thrombosis Details Deuruxolitinib Miconazole Aloe Vesta Antifungal Increased deuruxolitinib exposure and an increased risk of deuruxolitinib-related adverse effects such as thrombosis Details Deuruxolitinib Mifepristone Korlym Increased deuruxolitinib exposure and an increased risk of deuruxolitinib-related adverse effects such as thrombosis Details Deuruxolitinib Nitisinone Increased deuruxolitinib exposure and an increased risk of deuruxolitinib-related adverse effects such as thrombosis Details Deuruxolitinib Oxandrolone Oxandrin Increased deuruxolitinib exposure and an increased risk of deuruxolitinib-related adverse effects such as thrombosis Details Deuruxolitinib Phenylbutazone Equi-Phar Increased deuruxolitinib exposure and an increased risk of deuruxolitinib-related adverse effects such as thrombosis Details Deuruxolitinib Miconazole Buccal Oravig Increased deuruxolitinib exposure and an increased risk of deuruxolitinib-related adverse effects such as thrombosis Details Deuruxolitinib Miconazole Topical Aloe Vesta Antifungal Increased deuruxolitinib exposure and an increased risk of deuruxolitinib-related adverse effects such as thrombosis Details Deuruxolitinib Miconazole Vaginal Lagicam Increased deuruxolitinib exposure and an increased risk of deuruxolitinib-related adverse effects such as thrombosis DetailsMajor
Deuruxolitinib Capecitabine Xeloda Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Deuruxolitinib Adenovirus Vaccine Type 4, Live An increased risk of drug-drug interactions Details Deuruxolitinib Adenovirus Vaccine Type 7, Live An increased risk of drug-drug interactions Details Deuruxolitinib Apalutamide Erleada Reduced CYP3A4/CYP2C9 substrate exposure Details Deuruxolitinib Bacillus Of Calmette And Guerin Vaccine, Live An increased risk of drug-drug interactions Details Deuruxolitinib Cholera Vaccine, Live An increased risk of drug-drug interactions Details Deuruxolitinib Dengue Tetravalent Vaccine, Live An increased risk of drug-drug interactions Details Deuruxolitinib Deutivacaftor Increased CYP2C9 substrate exposure Details Deuruxolitinib Doxifluridine Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Deuruxolitinib Ebola Zaire Vaccine, Live An increased risk of drug-drug interactions Details Deuruxolitinib Enzalutamide Xtandi Reduced deuruxolitinib exposure and reduced efficacy of deuruxolitinib Details Deuruxolitinib Erythromycin Erythrocin Stearate Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Deuruxolitinib Fluorouracil Adrucil Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Deuruxolitinib Influenza Virus Vaccine, Live An increased risk of drug-drug interactions Details Deuruxolitinib Measles Virus Vaccine, Live An increased risk of drug-drug interactions Details Deuruxolitinib Mumps Virus Vaccine, Live An increased risk of drug-drug interactions Details Deuruxolitinib Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Deuruxolitinib Poliovirus Vaccine, Live An increased risk of drug-drug interactions Details Deuruxolitinib Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Deuruxolitinib Rifampin Rifadin Reduced deuruxolitinib exposure and reduced efficacy of deuruxolitinib Details Deuruxolitinib Rotavirus Vaccine, Live An increased risk of drug-drug interactions Details Deuruxolitinib Rubella Virus Vaccine, Live An increased risk of drug-drug interactions Details Deuruxolitinib Smallpox Monkeypox Vaccine An increased risk of drug-drug interactions Details Deuruxolitinib Tegafur Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Deuruxolitinib Typhoid Vaccine, Live Vivotif An increased risk of drug-drug interactions Details Deuruxolitinib Varicella Virus Vaccine, Live An increased risk of drug-drug interactions Details Deuruxolitinib Voriconazole Vfend Increased CYP3A4/CYP2C9 substrate exposure and an increased of CYP3A4/CYP2C9 substrates-related adverse effects DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacistEducational information only, not medical advice. Always confirm interactions with your pharmacist
or prescriber before making any change to your medications.